M
Mariam M. Konaté
Researcher at National Institutes of Health
Publications - 17
Citations - 433
Mariam M. Konaté is an academic researcher from National Institutes of Health. The author has contributed to research in topics: NADPH oxidase & Cancer. The author has an hindex of 9, co-authored 13 publications receiving 181 citations. Previous affiliations of Mariam M. Konaté include Columbia University.
Papers
More filters
Journal ArticleDOI
TPM, FPKM, or Normalized Counts? A Comparative Study of Quantification Measures for the Analysis of RNA-seq Data from the NCI Patient-Derived Models Repository.
Yingdong Zhao,Ming-Chung Li,Mariam M. Konaté,Li Chen,Biswajit Das,Chris Karlovich,P. Mickey Williams,Yvonne A. Evrard,James H. Doroshow,Lisa M. McShane +9 more
TL;DR: This is the first comparative study of RNA-seq data quantification measures conducted on PDX models, which are known to be inherently more variable than cell line models, and results reveal that hierarchical clustering on normalized count data tended to group replicate samples from the same PDX model together more accurately than TPM and FPKM data.
Journal ArticleDOI
Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas.
Tony Navas,Robert J. Kinders,Scott M. Lawrence,Katherine V. Ferry-Galow,Suzanne Borgel,Melinda G. Hollingshead,Apurva K. Srivastava,Sergio Y. Alcoser,Hala R. Makhlouf,Rodrigo F. Chuaqui,Deborah Wilsker,Mariam M. Konaté,Sarah B. Miller,Andrea Regier Voth,Li Chen,Tomas Vilimas,Jyothi Subramanian,Larry Rubinstein,Shivaani Kummar,Alice P. Chen,Donald P. Bottaro,James H. Doroshow,Ralph E. Parchment +22 more
TL;DR: The phenotypic plasticity conferred on carcinoma cells by EMT allows for rapid adaptation to cytotoxic or molecularly-targeted therapy and could create a form of acquired drug resistance that is transient in nature.
Journal ArticleDOI
The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel.
Anne Monks,Yingdong Zhao,Curtis Hose,Hossein A. Hamed,Julia Krushkal,Jianwen Fang,Dmitriy Sonkin,Alida Palmisano,Eric C. Polley,Laura K. Fogli,Mariam M. Konaté,Sarah B. Miller,Melanie A. Simpson,Andrea Regier Voth,Ming Chung Li,Erik Harris,Xiaolin Wu,John Connelly,Annamaria Rapisarda,Beverly A. Teicher,Richard Simon,James H. Doroshow +21 more
TL;DR: The NCI Transcriptional Pharmacodynamics Workbench represents the most extensive compilation to date of directly measured longitudinal transcriptional responses to anticancer agents across a thoroughly characterized ensemble of cancer cell lines.
Journal ArticleDOI
Inhibiting the Activity of NADPH Oxidase in Cancer.
TL;DR: This work has shown that large drug screens and rational design efforts have yielded inhibitor compounds, such as the diphenylene iodonium (DPI) analog series developed by the group, with increased selectivity and potency over "first generation" NOX inhibitors such as apocynin and DPI.
Journal ArticleDOI
Characterization of potent and selective iodonium-class inhibitors of NADPH oxidases
Jiamo Lu,Prabhakar Risbood,Charles T. Kane,Tafazzal Hossain,Larry D. Anderson,Kimberly Hill,Anne Monks,Yongzhong Wu,Smitha Antony,Agnes Juhasz,Han Liu,Guojian Jiang,Erik Harris,Krishnendu Roy,Jennifer L. Meitzler,Mariam M. Konaté,James H. Doroshow +16 more
TL;DR: Iodonium analogs with anticancer activity, including the first generation of targeted agents with improved specificity against DUOX2, may provide a novel therapeutic approach to NOX-driven tumors.